Craig-Hallum Maintains Guardant Health(GH.US) With Buy Rating
Craig-Hallum Keeps Their Buy Rating on Guardant Health (GH)
Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation?
Guardant Health Is Maintained at Outperform by Leerink Partners
Guardant Health Analyst Ratings
Leerink Partners Maintains Guardant Health(GH.US) With Buy Rating, Cuts Target Price to $50
Express News | Guardant Health Inc : Leerink Partners Cuts Target Price to $50 From $60
Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024
FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test
What You Can Learn From Guardant Health, Inc.'s (NASDAQ:GH) P/S
Guardant Health Announces Journal 'Nature Medicine' Published Results From SCRUM-Japan GOZILA Study
GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long
Morgan Stanley Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $46
Morgan Stanley analyst Tejas Savant maintains $Guardant Health(GH.US)$ with a buy rating, and maintains the target price at $46.According to TipRanks data, the analyst has a success rate of 41.1%
The Battle Brewing Over Blood Tests for Cancer -- Heard on the Street -- WSJ
ITeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types
Guardant Health Shares Are Trading Higher After the Company Partnered With Agostino Gemelli University Polyclinic Foundation to Launch an In-house Liquid Biopsy Testing Service Using Guardant360 CDx.
Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy
Guardant Health (NASDAQ:GH Shareholders Incur Further Losses as Stock Declines 4.3% This Week, Taking Three-year Losses to 81%